Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Common Equity (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Common Equity for 16 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 7.4% to $24.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Dec 2025, up 7.4% year-over-year, with the annual reading at $24.5 million for FY2025, 7.4% up from the prior year.
  • Common Equity hit $24.5 million in Q4 2025 for Cumberland Pharmaceuticals, down from $26.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $47.8 million in Q2 2021 to a low of $22.9 million in Q4 2024.
  • Historically, Common Equity has averaged $34.2 million across 5 years, with a median of $35.8 million in 2022.
  • Biggest five-year swings in Common Equity: plummeted 31.37% in 2024 and later grew 7.4% in 2025.
  • Year by year, Common Equity stood at $42.6 million in 2021, then fell by 15.56% to $36.0 million in 2022, then decreased by 18.66% to $29.3 million in 2023, then dropped by 21.89% to $22.9 million in 2024, then grew by 7.4% to $24.5 million in 2025.
  • Business Quant data shows Common Equity for CPIX at $24.5 million in Q4 2025, $26.1 million in Q3 2025, and $27.7 million in Q2 2025.